Formulation And Evaluation of Bilayer Tablets of Teneligliptin by Using Liquid Solid Compact Technology

Teneligliptin is an antidiabetic medication and belongs to BCS class II drugs. The present study aims at the preparation of liquisolid compact of teneligliptin with an aim to improve the solubility of the drug. The liquid solid system uses a non-volatile solvent to dissolve the drug. The drug's suspension or solution is transformed into a free-flowing, dry, and compressible powder by mixing it with a statistically determined amount of coating and carrier material. In this study Microcrystalline cellulose and Aerosil were used as carrier and coating material respectively. The non-volatile solvent that was used is propylene glycol. Nine formulations with varying excipient ratios were created, and their flowability and compressibility were assessed. A study on the interaction between drugs and excipients was conducted using Fourier transform infrared spectroscopy (FTIR). The optimized formulations were evaluated for flowability, compressibility study, comparative dissolution study with pure drug. The improved formulations exhibited good compression characteristics and flow properties. The medication and excipient did not physically interact, according to the FTIR analysis. The comparative dissolution study of the optimized formulations with the pure drug revealed significant improvement of solubility of teneligliptin in liquid solid compact. The diffusion exponent (n) of Korsmeyer-peppas model was found to be non-fickian. The results showed that liquid solid had illustrated significantly higher drug release rates than those of expectedly made was due to an increment in wetting properties and surface of sedate accessible for disintegration. Therefore, it can be concluded that a free flowing, non-adherent, dry and compressible powder of teneligliptin can be prepared using liquid solid compact technology.